---
title: "Parvinder Singh Hyare Backs Obsidian Deal at Galera Therapeutics with 6.65% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289517633.md"
description: "Parvinder Singh Hyare disclosed a 6.65% stake in Galera Therapeutics, holding over 13.5 million shares following the conversion of preferred stock. As CEO of Valorum Biologic, Hyare signed a support agreement to vote in favor of Galera's merger with Obsidian Therapeutics. He retains flexibility to adjust his holdings based on market conditions but currently supports the deal without seeking immediate corporate changes."
datetime: "2026-06-11T21:36:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289517633.md)
  - [en](https://longbridge.com/en/news/289517633.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289517633.md)
generator: "portal-rs"
---

# Parvinder Singh Hyare Backs Obsidian Deal at Galera Therapeutics with 6.65% Stake

Parvinder Singh Hyare disclosed a 6.65% stake in Galera Therapeutics, Inc., totaling 13,521,921 common shares. The filing, accepted on June 11, 2026, follows Galera’s May 15, 2026 mandatory conversion of Hyare’s Series B preferred shares into common stock. The move positions Hyare as a meaningful holder ahead of Galera’s planned merger with Obsidian Therapeutics.

**Investor Intent**

Hyare agreed to support Galera’s pending combination with Obsidian Therapeutics. Under a Stockholder Support Agreement signed on April 14, 2026, he committed to “vote all of \[his\] eligible shares” in favor of approving the mergers and the related actions, and “against any proposal made in opposition to, or in competition with” the deal.

Beyond that commitment, Hyare does not outline specific plans to push corporate changes. He notes he may buy more shares or sell some of his holdings in the future as he evaluates Galera’s business and the market.

**Investor's Background**

Parvinder Singh Hyare is an American investor and the Chief Executive Officer of Valorum Biologic, Inc. He focuses on healthcare and biotechnology ventures, aligning capital with drug development and clinical-stage assets. Hyare brings operating experience from the sector to his investing decisions.

Original SEC Filing: Galera Therapeutics, Inc. \[ GRTX \] - SCHEDULE 13D - Jun. 11, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [GRTX.US](https://longbridge.com/en/quote/GRTX.US.md)
- [GRTXD.US](https://longbridge.com/en/quote/GRTXD.US.md)

## Related News & Research

- [Seven Elements clarifies AGM poll results, corrects vote percentages to 100% from 0%](https://longbridge.com/en/news/296772363.md)
- [Tempest Therapeutics special meeting adjourned after proposal fell short of required votes](https://longbridge.com/en/news/296266762.md)
- [LPSN: Adjournment was approved to reconvene on September 2nd after insufficient votes for the merger](https://longbridge.com/en/news/296507504.md)
- [Capstone Energy+: All proposals passed, including director elections and auditor ratification, with no questions submitted](https://longbridge.com/en/news/296520458.md)
- [Does Unusual Machines (UMAC) Pairing EY With Easier Vote Standards Reframe Its Governance Power Balance?](https://longbridge.com/en/news/296845891.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**